mTOR

Mammalian target of Rapamycin

mTOR

mTOR Isoform Specific Products:

mTOR Isoform Comparison

mTOR Related Products (326)
Antibodies (14)
mTOR Signaling Pathway
mTOR Isoform Comparison

By Effects:	Control (1) Inhibitors (274) Substrate (1) Antagonist (1) Activators (28) Modulators (6) p53 Inhibitor (1)

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-114267

Cbz-B3A	Inhibitor	≥98.0%
Cbz-B3A is a potent and selective inhibitor of mTORC1 signaling that appear to bind to ubiquilins 1, 2, and 4, and Cbz-B3A inhibits the phosphorylation of eIF4E-binding protein 1 (4EBP1).

HY-B1787

Sulindac sulfone	Inhibitor	98.10%
Sulindac sulfone is an mTORC1 pathway inhibitor and a metabolite of Sulindac. Sulindac sulfone inhibits colon cancer cell growth and induces cell cycle arrest. Sulindac sulfone is used in cancer research.

HY-17471AR

Metformin (hydrochloride) (Standard)	Inhibitor	99.97%
Metformin hydrochloride (Standard) is the analytical standard of Metformin (hydrochloride). This product is intended for research and analytical applications. Metformin (1,1-Dimethylbiguanide) hydrochloride inhibits the mitochondrial respiratory chain in the liver, leading to AMPK activation and enhancing insulin sensitivity, and can be used in the study of type 2 diabetes. Metformin hydrochloride also inhibits liver oxidative stress, nitrosative stress, inflammation, and apoptosis caused by liver ischemia/reperfusion injury. In addition, metformin hydrochloride regulates the expression of autophagy-related proteins by activating AMPK and inhibiting the mTOR signaling pathway, thereby inducing tumor cell autophagy and inhibiting the growth of renal cell carcinoma in vitro and in vivo.

HY-N2303

Eriocalyxin B	Inhibitor	99.93%
Eriocalyxin B is a diterpenoid compound that can be isolated from Chinese herb Isodon eriocalyx. Eriocalyxin B exhibits multiple activities, such as anti-cancer, anti-inflammatory, and inhibition of adipogenesis. Eriocalyxin B is capable of inducing apoptosis and autophagy in tumor cells. Eriocalyxin B can be used in the research of cancers, autoimmune diseases, and other conditions.

HY-N0486R

L-Leucine (Standard)	Activator
L-Leucine (Standard) is the analytical standard of L-Leucine. This product is intended for research and analytical applications. L-Leucine is an essential branched-chain amino acid (BCAA), which activates the mTOR signaling pathway.

HY-111065

OXA-01	Inhibitor
OXA-01 is a potent mTORC1 and mTORC2 inhibitor, with IC₅₀ values of 29 nM and 7 nM, respectively.

HY-10218S

Everolimus-d₄	Inhibitor
Everolimus-d₄ is the deuterium labeled Everolimus. Everolimus (RAD001) is a Rapamycin derivative and a potent, selective and orally active mTOR1 inhibitor. Everolimus binds to FKBP-12 to generate an immunosuppressive complex. Everolimus inhibits tumor cells proliferation and induces cell apoptosis and autophagy. Everolimus has potent immunosuppressive and anticancer activities[1][2].

HY-147284

PI3K-IN-37	Inhibitor	≥99.0%
PI3K-IN-37 (Example 84.1) is a PI3K α/β/δ inhibitor with IC₅₀s of 6, 8, 4 nM, respectively. PI3K-IN-37 can also inhibit mTOR (IC₅₀=4 nM).

HY-N4315

Pomiferin	Inhibitor	98.98%
Pomiferin (NSC 5113) acts as an potential inhibitor of HDAC, with an IC₅₀ of 1.05 μM, and also potently inhibits mTOR (IC₅₀, 6.2 µM).

HY-10620

PI3K-IN-22	Inhibitor	99.50%
PI3K-IN-22 is a PI3Kα/mTOR dual kinase inhibitor. PI3K-IN-22 has IC₅₀s of 0.9, 0.6 nM for PI3Kα and mTOR, respectively. PI3K-IN-22 can be used for the research of cancer.

HY-N6996R

Methyl Eugenol (Standard)	Inhibitor
Methyl Eugenol (Standard) is the analytical standard of Methyl Eugenol. This product is intended for research and analytical applications. Methyl Eugenol is a bait that has oral activity against oriental fruit fly (Hendel).Methyl Eugenol has anti-cancer and anti-inflammatory activities. Methyl Eugenol can induce Autophagy in cells. Methyl Eugenol can be used in the study of intestinal ischemia/reperfusion injury.

HY-15271A

WYE-687 dihydrochloride	Inhibitor	≥98.0%
WYE-687 dihydrochloride is an ATP-competitive mTOR inhibitor with an IC₅₀ of 7 nM. WYE-687 dihydrochloride concurrently inhibits activation of mTORC1 and mTORC2. WYE-687 also inhibits PI3Kα and PI3Kγ with IC₅₀s of 81 nM and 3.11 μM, respectively.

HY-156027

SIRT6-IN-3	Inhibitor	98.19%
SIRT6-IN-3 (compound 8a) is a selective inhibitor of SIRT6 (IC₅₀=7.49 μM). SIRT6-IN-3 inhibits pancreatic ductal adenocarcinoma (PDAC) cells proliferation and induces apoptosis. SIRT6-IN-3 increases the sensitivity of cancer cells to gemcitabine (HY-17026) via blocking the DNA damage repair pathway. SIRT6-IN-3 is used in pancreatic cancer research.

HY-N3628

Coronarin A	Inhibitor	≥98.0%
Coronarin A is an orally active natural compound that inhibits mTORC1 and S6K1 to increase IRS1 activity. Coronarin A shows anti-inflammatory activity and can also be used for type 2 diabetes mellitus research.

HY-109633

PI3K-IN-18	Inhibitor	≥99.0%
PI3K-IN-18 (Compound 1) is a PI3K inhibitor, and can also effectively inhibit the homologous enzymemTOR. The IC₅₀ values of PI3K-IN-18 for mTOR and PI3K-α were 49 nM and 41 nM, respectively.

HY-N5136

25(R,S)-Ruscogenin	Inhibitor	99.83%
Ruscogenin suppresses HCC metastasis by reducing the expression of MMP-2, MMP-9, uPA, VEGF and HIF-1α via regulating the PI3K/Akt/mTOR signaling pathway. And Ruscogenin alleviates LPS-induced pulmonary endothelial cell apoptosis by su

HY-P3072

Mastoparan 17	Control	98.15%
Mastoparan 17 is a tetradecapeptide. Mastoparan 17 is an inactive analogue of Mastoparan (HY-P0246) .

HY-155066

FD274	Inhibitor	99.45%
FD274 is a highly potent PI3K/mTOR dual inhibitor with IC₅₀s of 0.65 nM, 1.57 nM, 0.65 nM, 0.42 nM, and 2.03 nM against PI3Kα/β/γ/δ and mTOR, respectively. FD274 exhibits significant anti-proliferation of AML cell lines (HL-60 and MOLM-16). FD274 demonstrates dose-dependent inhibition of tumor growth in the HL-60 xenograft model. FD274 has the potential for acute myeloid leukemia research.

HY-N0486S12

L-Leucine-d₂	Activator	≥99.0%
L-Leucine-d₂ is the deuterium labeled L-Leucine. L-Leucine is an essential branched-chain amino acid (BCAA), which activates the mTOR signaling pathway[1].

HY-157169

IBL-302	Inhibitor	98.21%
IBL-302 (AMU302) is an orally available dual-signaling inhibitor of PIM and PI3K/AKT/mTOR with activity against breast cancer and neuroblastoma. IBL-302 demonstrated in vivo efficacy in a nude mouse xenograft model, inhibiting trastuzumab (HY-P9907) resistance challenges. IBL-302 also enhances the effects of common cytotoxic chemotherapy drugs cisplatin (HY-17394), doxorubicin (HY-15142A), and etoposide (HY-13629).

SLC7A5 SLC3A2 Sestrin1/2 CASTOR1 CASTOR1 GATOR2 GATOR1 FLCN-FNIP2 RagA/B RagC/D mTORC1 p14 MP1 p18 v-ATPase SLC38A9 Glucose GLUT4 DNA Damage p53 Sestrin1/2 AMPK IKKβ LKB1 RHEB FKBP12 Rapamycin mTOR mTORC1 DEPTOR RAPTOR PRAS40 mLST8 TNF Receptor TNF Growth factors GFRs: EGFRs, IGF1R, Insulin Receptor, FGFR and Met SOS SHC GRB2 IRS1 PI3K Ras Raf MEK ERK RSK TSC2 TSC1 TBC1D7 REDD1 4EBP eIF4E S6K eIF4B PDCD4 SKAR ATF4 MTHFD2 CAD HIF1α Lipin1 ULK1 UVRAG/
ATG14L TFEB ERK5 PGC1-α Autophage Proteasome
assembly SREBP Glucose
metabolism Apoptosis FOXO1,3 GRB10 S6K PTEN PDK1 Akt SGK Ion
transport Rho kinase PKC Actin/
cytoskeleton TSC2 TSC1 TBC1D7 mTOR DEPTOR RICTOR mSIN1 PROTOR mLST8 RAC1 GSK-3β Wnt mTORC2

Download mTOR Signaling Pathway Map.

The mammalian target of rapamycin (mTOR) signaling pathway integrates both intracellular and extracellular signals and serves as a central regulator of cell metabolism, growth, proliferation and survival^[1]. mTOR is the catalytic subunit of two distinct complexes called mTORC1 and mTORC2. mTORC1 comprises DEPTOR, PRAS40, RAPTOR, mLST8, mTOR, whereas mTORC2 comprises DEPTOR, mLST8, PROTOR, RICTOR, mSIN1, mTOR^[2]. Rapamycin binds to FKBP12 and inhibits mTORC1 by disrupting the interaction between mTOR and RAPTOR. mTORC1 negatively regulates autophagy through multiple inputs, including inhibitory phosphorylation of ULK1 and TFEB. mTORC1 promotes protein synthesis through activation of the translation initiation promoter S6K and through inhibition of the inhibitory mRNA cap binding 4E-BP1, and regulates glycolysis through HIF-1α. It promotes de novo lipid synthesis through the SREBP transcription factors. mTORC2 inhibits FOXO1,3 through SGK and Akt, which can lead to increased longevity. The complex also regulates actin cytoskeleton assembly through PKC and Rho kinase^[3].

Growth factors: Growth factors can signal to mTORC1 through both PI3K-Akt and Ras-Raf-MEK-ERK axis. For example, ERK and RSK phosphorylate TSC2, and inhibit it.

Insulin Receptor: The activated insulin receptor recruits intracellular adaptor protein IRS1. Phosphorylation of these proteins on tyrosine residues by the insulin receptor initiates the recruitment and activation of PI3K. PIP3 acts as a second messenger which promotes the phosphorylation of Akt and triggers the Akt-dependent multisite phosphorylation of TSC2. TSC is a heterotrimeric complex comprised of TSC1, TSC2, and TBC1D7, and functions as a GTPase activating protein (GAP) for the small GTPase Rheb, which directly binds and activates mTORC1. mTORC2 primarily functions as an effector of insulin/PI3K signaling.

Wnt: The Wnt pathway activates mTORC1. Glycogen synthase kinase 3β (GSK-3β) acts as a negative regulator of mTORC1 by phosphorylating TSC2. mTORC2 is activated by Wnt in a manner dependent on the small GTPase RAC1^[4].

Amino acids: mTORC1 senses both lysosomal and cytosolic amino acids through distinct mechanisms. Amino acids induce the movement of mTORC1 to lysosomal membranes, where the Rag proteins reside. A complex named Ragulator, interact with the Rag GTPases, recruits them to lysosomes through a mechanism dependent on the lysosomal v-ATPase, and is essential for mTORC1 activation. In turn, lysosomal recruitment enables mTORC1 to interact with GTP-bound RHEB, the end point of growth factor. Cytosolic leucine and arginine signal to mTORC1 through a distinct pathway comprised of the GATOR1 and GATOR2 complexes.

Stresses: mTORC1 responds to intracellular and environmental stresses that are incompatible with growth such as low ATP levels, hypoxia, or DNA damage. A reduction in cellular energy charge, for example during glucose deprivation, activates the stress responsive metabolic regulator AMPK, which inhibits mTORC1 both indirectly, through phosphorylation and activation of TSC2, as well as directly through the phosphorylation of RAPTOR. Sestrin1/2 are two transcriptional targets of p53 that are implicated in the DNA damage response, and they potently activate AMPK, thus mediating the p53-dependent suppression of mTOR activity upon DNA damage. During hypoxia, mitochondrial respiration is impaired, leading to low ATP levels and activation of AMPK. Hypoxia also affects mTORC1 in AMPK-independent ways by inducing the expression of REDD1, the protein products of which then suppress mTORC1 by promoting the assembly of TSC1-TSC2^[2].

Reference:

[1]. Laplante M, et al.mTOR signaling at a glance.J Cell Sci. 2009 Oct 15;122(Pt 20):3589-94.
[2]. Zoncu R, et al. mTOR: from growth signal integration to cancer, diabetes and ageing.Nat Rev Mol Cell Biol. 2011 Jan;12(1):21-35.
[3]. Johnson SC, et al. mTOR is a key modulator of ageing and age-related disease.Nature. 2013 Jan 17;493(7432):338-45.
[4]. Shimobayashi M, et al. Making new contacts: the mTOR network in metabolism and signalling crosstalk.Nat Rev Mol Cell Biol. 2014 Mar;15(3):155-62.

Rapamycin		mTOR, IC₅₀: 0.1 nM (in HEK293 cells )		99.94%
MHY1485		mTORC1	mTORC2	99.93%
Everolimus		mTOR, IC₅₀: 5-6 nM		99.85%
Torin 1	mTOR, IC₅₀: 3 nM	mTORC1, IC₅₀: 2-10 nM	mTORC2, IC₅₀: 2-10 nM	99.28%
AZD-8055	mTOR, IC₅₀: 0.8 nM			99.60%
Sapanisertib	mTOR, IC₅₀: 1 nM			99.66%
Salidroside	mTOR			99.90%
Temsirolimus		mTOR, IC₅₀: 1.76 μM		99.56%
L-Leucine		mTORC1		99.79%
Dactolisib	mTOR, IC₅₀: 20.7 nM			99.94%
Torin 2	mTOR, IC₅₀: 2.81 nM mTOR, EC₅₀: 0.25 nM (Cell Assay)			99.65%
PI-103		mTORC1, IC₅₀: 20 nM	mTORC2, IC₅₀: 83 nM	99.82%
RMC-5552		mTORC1		98.10%
Omipalisib		mTORC1, Ki: 0.18 nM	mTORC2, Ki: 0.3 nM	99.94%
Camonsertib	mTOR, IC₅₀: 120 nM			99.75%
RapaLink-1	mTOR			99.92%
3BDO	mTOR			99.93%
JR-AB2-011			mTORC2, IC₅₀: 0.36 μM	98.15%
Dihydromyricetin		mTORC1	mTORC2	99.73%
Torkinib	mTOR, IC₅₀: 8 nM	mTORC1, IC₅₀: 30 nM	mTORC2, IC₅₀: 58 nM	99.03%
Aloe emodin			mTORC2	98.32%
hSMG-1 inhibitor 11j	mTOR, IC₅₀: 50 nM			99.82%
Vistusertib	mTOR, IC₅₀: 2.81 nM			99.32%
KU-0063794		mTORC1, IC₅₀: 10 nM	mTORC2, IC₅₀: 10 nM	99.67%
Gedatolisib	mTOR, IC₅₀: 1.6 nM			99.68%
PF-04691502	mTOR, Ki: 16 nM			99.91%
Paxalisib	mTOR, Ki: 70 nM			99.63%
hSMG-1 inhibitor 11e	mTOR, IC₅₀: 45 nM			99.81%
Samotolisib	mTOR, IC₅₀: 165 nM			99.27%
Apitolisib	mTOR, Ki: 17 nM			99.29%
Bimiralisib	mTOR, IC₅₀: 89 nM			99.80%
CC-115	mTOR, IC₅₀: 21 nM			99.82%
Dactolisib Tosylate	mTOR, IC₅₀: 20.7 nM			99.87%
Voxtalisib	mTOR, IC₅₀: 157 nM	mTORC1, IC₅₀: 160 nM	mTORC2, IC₅₀: 910 nM	99.02%
Onatasertib	mTOR, IC₅₀: 16 nM			99.13%
BGT226	mTOR			99.51%
GSK1059615	mTOR, IC₅₀: 12 nM			≥99.0%
WYE-132	mTOR, IC₅₀: 0.19 nM			99.90%
Ridaforolimus		mTOR		99.75%
mTOR inhibitor-3	mTOR, Ki: 1.5 nM			99.09%
PKI-402	mTOR, IC₅₀: 3 nM			98.43%
PP121	mTOR, IC₅₀: 10 nM			98.67%
OSI-027	mTOR, IC₅₀: 4 nM	mTORC1, IC₅₀: 22 nM	mTORC2, IC₅₀: 65 nM	99.95%
VS-5584	mTOR, IC₅₀: 37 nM			99.14%
GNE-317	mTOR			99.14%
PI-103 Hydrochloride		mTORC1, IC₅₀: 20 nM	mTORC2, IC₅₀: 83 nM	98.55%
CZ415	mTOR, pIC₅₀: 8.07			98.39%
PQR530	mTOR, Kd: 0.33 nM			99.98%
BGT226 maleate	mTOR			99.92%
(+)-Usnic acid		mTORC1	mTORC2	99.63%
ETP-46464	mTOR, IC₅₀: 0.6 nM			99.55%
Palomid 529		TORC1	TORC2	99.37%
CC-115 hydrochloride	mTOR, IC₅₀: 21 nM			98.03%
PQR620		mTORC1	mTORC2	98.01%
GDC-0349	mTOR, Ki: 3.8 nM			98.02%
PF-04979064	mTOR, Ki: 1.42 nM			99.54%
GNE-493	mTOR, IC₅₀: 30 nM			99.81%
WAY-600	mTOR, IC₅₀: 9 nM			99.75%
WYE-354	mTOR, IC₅₀: 5 nM			98.04%
HDACs/mTOR Inhibitor 1	mTOR, IC₅₀: 1.2 nM			99.01%
PI3K/mTOR Inhibitor-2	mTOR, IC₅₀: 4.7 nM			99.10%
Hederacolchiside A1	mTOR			≥99.0%
NSC781406	mTOR, IC₅₀: 5.4 nM			99.97%
MTI-31	mTOR, Ki: 0.2 nM mTOR, IC₅₀: 39 nM (100 μM ATP)			99.98%
mTOR inhibitor-8	mTOR			98.14%
MT 63-78		mTORC1		98.50%
PI3K/mTOR Inhibitor-4	mTOR, IC₅₀: 13.85 nM
GNE-477	mTOR, Ki: 21 nM			98.75%
ETP-45658	mTOR, IC₅₀: 152.0 nM			98.97%
PKI-179	mTOR, IC₅₀: 0.42 nM			≥98.0%
Zederone	mTOR			99.61%
Rotundic acid	mTOR			99.41%
XL388	mTOR, IC₅₀: 9.9 nM			99.74%
FT-1518		mTORC1	mTORC2	98.62%
HTH-01-091	mTOR, IC₅₀: 632 nM			98.64%
AZD3147		mTORC1	mTORC2	99.93%
WYE-687	mTOR, IC₅₀: 7 nM			98.05%
TML-6	mTOR			99.01%
PKI-179 hydrochloride	mTOR, IC₅₀: 0.42 nM			99.66%
CC214-2		mTORC1	mTORC2	98.41%
8-Aminoadenosine	mTOR			99.94%
GNE-490	mTOR, IC₅₀: 750 nM
PI3K-IN-37	mTOR, IC₅₀: 4 nM			≥99.0%
Pomiferin	mTOR, IC₅₀: 6.2 μM			98.98%
PI3K-IN-22	mTOR, IC₅₀: 0.6 nM			99.50%
WYE-687 dihydrochloride	mTOR, IC₅₀: 7 nM			≥98.0%
Coronarin A		mTORC1		≥98.0%
PI3K-IN-18	mTOR, IC₅₀: 49 nM			≥99.0%
FD274	mTOR, IC₅₀: 2.03 nM			99.45%
PI3Kα/mTOR-IN-1	mTOR, Ki: 10.6 nM			99.30%
HSP90/mTOR-IN-1	mTOR, IC₅₀: 29 nM
PI3K/mTOR Inhibitor-1	mTOR, IC₅₀: 186 nM
mTOR inhibitor-2	mTOR, IC₅₀: 7 nM
PI3K/mTOR Inhibitor-9	mTOR, IC₅₀: 38 nM (phospho-S6 cellular assay) mTOR, IC₅₀: 16 nM (Ser240/244 cellular assay)
SN32976	mTOR, IC₅₀: 194 nM			99.49%
ATM Inhibitor-3	mTOR
ATM Inhibitor-4	mTOR
mTOR/HDAC-IN-1	mTOR, IC₅₀: 0.49 nM
PI3K/mTOR Inhibitor-3	mTOR
PI3Kα-IN-5	mTOR, IC₅₀: 3.3 nM
PI3K/mTOR Inhibitor-12	mTOR, IC₅₀: 3.12 nM
PI3K/mTOR Inhibitor-8	mTOR, IC₅₀: 12 nM
ATR-IN-20	mTOR, IC₅₀: 18 nM
Antifungal agent 106	mTOR, IC₅₀: 0.8 μM
PI3K/mTOR Inhibitor-14	mTOR, IC₅₀: 10.1 nM
mTOR/HDAC6-IN-1	mTOR, IC₅₀: 133.7 nM
mTOR inhibitor-13	mTOR, IC₅₀: 0.29 nM
mTOR inhibitor-17	mTOR, IC₅₀: 0.68 nM
mTOR inhibitor-16	mTOR, IC₅₀: 1.25 nM
mTOR inhibitor-10	mTOR, IC₅₀: 0.7 nM

Name
Email *

	Sorry, but the email address you supplied was invalid.

mTOR

mTOR

mTOR Isoform Specific Products:

mTOR Isoform Specific Products:

mTOR Related Products (326)

Antibodies (14)

mTOR Signaling Pathway

mTOR Isoform Comparison

mTOR Related Products (326):